Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight

INTRODUCTION: Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. METHODS: 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. RESULTS: Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). CONCLUSION: The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.

Authors

Institutions

Publication Details

Journal
Advances in Therapy
Published
2026-05-23
DOI
https://doi.org/10.1007/s12325-026-03615-2
Primary Topic
Obesity and Health Practices
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight

Hayley Karn, Lisa M. Neff, Claudine Clucas, Miriam Kimel et al.
Advances in Therapy
Obesity and Health Practices
article

Psychometric Validation of the Weight and Emotions Scale (WES) in Adults with Obesity or Overweight

Hayley Karn, Lisa M. Neff, Claudine Clucas, Miriam Kimel, Chisom Kanu, Kristina S. Boye, Iris Goetz
article en

Abstract

INTRODUCTION: Individuals with obesity or overweight experience a substantial socioemotional burden and lower quality of life. Existing patient-reported outcome (PRO) instruments do not adequately measure emotional functioning concepts important to individuals with obesity/overweight. This study describes the psychometric properties of the Weight and Emotions Scale (WES), a new PRO measure to evaluate emotional functioning in adults with obesity or overweight. METHODS: 120 adults completed two web-based surveys (baseline, week 2). Survey 1 comprised the 16-item WES, Control of Eating Questionnaire, Impact of Weight on Quality of Life-Lite Clinical Trials Version, Impact of Weight on Self-Perceptions Questionnaire, and Patient Global Impression of Severity (PGIS) 'Overall Emotional Impact of Weight.' Survey 2 included the WES and PGIS 'Overall Emotional Impact of Weight.' Factor structure, reliability, and validity of the WES were assessed. RESULTS: Exploratory factor analysis of the WES supported a two-factor structure as items loaded strongly (≥ 0.59) on factors corresponding to positive and negative feelings. The unidimensional framework was revised to include two WES domains ('Positive Feelings' [8 items] and 'Negative Feelings' [8 items]). The WES domain and total scores demonstrated excellent internal consistency (Cronbach's alpha ≥ 0.90) and good test-retest reliability (intraclass correlation coefficient: 0.87-0.89). Convergent validity of the WES was demonstrated via large correlations with the Impact of Weight on Quality of Life-Lite Clinical Trials Version 'Psychosocial' score and items, Impact of Weight on Self-Perceptions Questionnaire total score, and PGIS 'Overall Emotional Impact of Weight.' Known-groups validity was demonstrated via higher WES domain and total scores in participants who reported feeling good about their weight (PGIS 'Overall Emotional Impact of Weight'). CONCLUSION: The final version of the WES with 16 items is a reliable and valid PRO measure for assessing emotional functioning in individuals with obesity or overweight, with potential utility in observational studies, clinical trials, and clinical practice.

Advances in Therapy
Eli Lilly (United States) (US), Thermo Fisher Scientific (United Kingdom) (GB), Thermo Fisher Scientific (Israel) (IL)
Eli Lilly and Company
Openalex Percentile: Top 2%
Obesity and Health Practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.